CM retweeted
No one cares as of now, but $PTN is $10MM MC and have a decent oral and injectable molecule with the same MOA.
The management is a disaster, true, but the discrepancy of $10MM vs. $10B is interesting at least.
$RYTM bidding war
RHYTHM PHARMACEUTICALS REPORTEDLY WORKING WITH GOLDMAN SACHS AS MULTIPLE POTENTIAL BUYERS CIRCLE FOLLOWING ASTRAZENECA'S REPORTED $10B OFFER — BETAVILLE
Prior to $AVTX HS ph2, I was negative because of Lutikizumab’s weak data.
However, $AVTX data came perfectly, and I realized this is not the mechanism, it’s that Lutikizumab is inferior to Abdakibart. Moreover, IL-1 affects IL-17 as well. Last, HS clinical development is heading into combination therapy.
8
819
CM retweeted
$SRPT catalysts upcoming catalysts include completion of ENDEAVOR Cohort 8
enrollment with ~25 non-ambulatory patients by YE26, followed by full 12-week data and planned
FDA engagement on potential label re-inclusion of non-ambulatory patients in 1Q27. We also
expect MAD cohort data for SRP-1001 (FSHD) and SRP-1003 (DM1) in 4Q26, initial proof-of-
biology data for SRP-1005 (Huntington’s) in 1H27, and FDA target action on the Vyondys
53/Amondys 45 sNDAs on Feb. 28, 2027
CM retweeted
$ABVX The drug is good to the point where if they had to pull a UCB and just launch it themselves and get to profitability, they can very credibly have a path there, especially if CD works. IMO you don't need M&A to have an attractive return on this if you're patient -- M&A just improves the IRR.
Smart combos are the most important piece now, either orals or LI injectables. Integrin, TL1a, and IL-23 all viable options. Would be curious to see a combo induction --> oral-only maintenance strategy w/ intermittant biologics as needed. My hypothesis is you get disease under control with multiple mechanisms to have the best chance at breaking the self-reinforcing inflammatory cycle and then maintain on oral obe for mucosal healing advantage/keep patients in remission, and can lifecycle manage as well.
Replying to @my_ueg
@my_ueg
Obefazimod data at #UEGW show that, in its ***100%*** advanced-treatment refractory population (which includes JAK failures), Obefazimod *still* produced a higher absolute AND placebo adjusted maintenance endoscopic remission rate than Rinvoq in its *overall population*, which of course included many AT-naive patients.
...Obefazimod showed a higher absolute and adjusted AT-IR ER rate than any P3 trial of ANY drug has ever shown in its OVERALL population.....versus the 100% advanced-treatment refractory population in Obefazimod's ABTECT trials.
Just insane efficacy. All from a safe once-daily pill with a novel MoA...
Replying to @my_ueg
@my_ueg
Obefazimod data at #UEGW show that, in its ***100%*** advanced-treatment refractory population (which includes JAK failures), Obefazimod *still* produced a higher absolute AND placebo adjusted maintenance endoscopic remission rate than Rinvoq in its *overall population*, which of course included many AT-naive patients.
...Obefazimod showed a higher absolute and adjusted AT-IR ER rate than any P3 trial of ANY drug has ever shown in its OVERALL population.....versus the 100% advanced-treatment refractory population in Obefazimod's ABTECT trials.
Just insane efficacy. All from a safe once-daily pill with a novel MoA...
$SRPT best muscle targeting indeed
investorrelations.sarepta.co…
9
676
CM retweeted
$HELP Since August 31, four senior executives and directors have collectively purchased approximately 788,000 shares for $9.7 million in the open market, including:
- Eric So, Executive Chairman: 295,000 shares / $3.57 million
- Paul Glavine, Chief Growth Officer: 390,000 shares / $4.72 million
- Michael Halstead, CEO: 100,000 shares / $1.35 million
- Greg Cavers, CFO: 3,000 shares / $38,730
These are open-market purchases made with personal capital, not stock grants or option exercises.
8:20 AM
CM retweeted
Fun bit of biotech history.
BMS acquired Amira in 2011 for $325M upfront for it's lead program against LPA1 for fibrosis. Amira was a "smart chemistry" play founded in 2005, backed by Versant with former Merck founders, including Peppi Prasit. That drug (BMS-986020/AM152) ended up seeing efficacy in Phase 2, but was terminated for hepatobiliary toxicity in 2018.
BMS scientists went back to discovery, armed with SAR from the first gen, and retooled to make admilparant... and here we are nearly a decade later with Phase 3 data.
LPA1 has been a well-credentialed fibrosis target for ages, and today's topline Ph 3 hit is the culmination of a continuous discovery and development campaign against LPA1 spanning over 20 years.
Drug R&D requires playing a very long game.
$BMY Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint
businesswire.com/news/home/2…
I think the $CTNM premarket weakness following $BMY's ALOFT readout misses an important distinction.
Admilparant's 60mg dose met the Phase 3 primary endpoint, validating LPA1 inhibition in IPF, while 120mg missed significance.
A 2025 Idorsia paper (Birker-Robaczewska et al) demonstrated that admilparant is a surmountable LPA1 antagonist with rapid dissociation from the receptor, allowing LPA signaling to recover relatively quickly.
In contrast, $CTNM's PIPE-791 has very slow association/dissociation kinetics and a long receptor residence time (koff = 0.00133 min⁻¹).
The readout validates the target while potentially highlighting the importance of molecule-specific binding kinetics.
To me, that's a potentially positive read-through for $CTNM, not a negative one.
2
18
3,802
CM retweeted
B | RILEY (a/o 10/1) reiterated $CUE Buy-$83 after its KOL event (n=2).
$CLDX $RHHBY - NVS SNY - REGN EVMN SPRY AZN IFRX NSRGY DBVT
AMGN BMY MRK NKTR COYA
B | RILEY said in its note: We reiterate our Buy rating and $83 PT on CUE following our 9/29 IgE-mediated diseases KOL event with Drs Dale Umetsu (allergy specialist) of UCSF and John Durkin (dermatologist) of University of New Mexico, which reviewed CUE-221's Ph2 CSU dataset (9/20 CUE-221 topline), Celldex's EMBARQ-CSU Ph3 (9/22 CLDX Ph3 readthrough) and translation into food allergy.
Both KOLs viewed the head-to-head comparative data vs. omalizumab as the most informative feature of the dataset, with Dr. Umetsu calling the outperformance surprising given how effective Xolair is, and both pointed to off-drug durability as what makes the profile clinically differentiating.
The open debate is mechanistic attribution, namely whether the efficacy tail through Wk28 could be convincingly proven to be driven by CD23-mediated suppression of IgE synthesis; implying PK alongside free and total IgE as the dataset that likely resolves that issue.
We anticipate IgE and PK/PD data disclosure in coming weeks as the next de-risking event, and total IgE off drug as the measure to anchor on, since omalizumab keeps it elevated for up to a year after the last dose.
Dr. Durkin described NVS' Rhapsido increasingly becoming his firstline CSU choice, positioned barzo as 2L+/reserved for most severe patients, and anticipates the newly approved omalizumab biosimilar related step edits to further raise the importance of a treat-and-extend dosing frequency profile pursued with CUE-221.
In food allergy, Dr. Umetsu indicated CUE-221 (higher-dose) offering promising safety/efficacy to get to 2,000 mg challenge, well above the 600 mg registrational precedent, alongside highest-IgE patients that Xolair dosing table excludes (including pediatrics).
The current ~$150M EV, relative to multiple transaction comps exceeding $1B+ presents a compelling entry point in advance of catalyst-dense 4Q/1H27.
BRiley🏁 $CUE Buy-$83 and said -- Cue is best understood as a new company.
$RHHBY - $NVS SNY - REGN CLDX SPRY EVMN AZN IFRX NSRGY DBVT
COYA NKTR AMGN BMY MRK
Here's what BRiley went on to say in its initiation report:
In April 2026 it brought in CEO Shao-Lee Lin, founder of ACELYRIN and formerly CSO at Horizon and head of therapeutic areas at AbbVie, and on the same day in-licensed a new lead drug, CUE 221, rebuilding the investment case around two immunology programs.
The near-term opportunity is allergy.
CUE-221 is an anti-IgE antibody in the same class as Xolair, the only approved drug in the category, with two differences: it neutralizes IgE at roughly four to eight times Xolair's potency, and it leaves intact CD23, the receptor through which the body suppresses its own IgE production and which Xolair blocks.
In a 15 patient first-in-human study in chronic hives, one dose at the two highest levels held free IgE undetectable for 14 weeks in every patient while drug levels fell more than 100-fold, a pattern a neutralizing antibody alone does not produce.
Licensor Ascendant is running a 145-patient placebo- and Xolair-controlled Ph2 in the same condition in China, with topline by end-3Q26.
We view it as a dose-selection and mechanism test, not a superiority trial, and a supportive result opens a global Ph2b in food allergy, where 33M Americans have one approved drug and where the two prior commercial attempts, Aimmune's Palforzia and DBV's patch, failed or stalled on delivery burden, not efficacy.
The longer-term upside is CUE-401, designed to convert attacking T cells into regulatory ones; IND and Ph1 start are guided for YE26.
Pro forma cash of ~$67M after the $50M July financing funds both programs through their next readouts. At a ~$234M EV, we believe the shares reflect neither.





















